Physician profile
Thomas Patrick Feeney
NPI 1588631568
$117,806.66
in general payments reported to CMS, 2019-2025
69 companies · $3,880 in 2025
The $3,880 reported for 2025 was more than what 90% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $7,347 · 2021: $29K · 2022: $28K · 2023: $17K · 2024: $13K · 2025: $3,880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Food and Beverage: $7,459 · Travel and Lodging: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,835.00 |
| Food and Beverage | $7,458.84 |
| Travel and Lodging | $316.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $56,811.16 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29,486.16 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $17,474.06 | 2019-2025 | Farxiga, Lokelma, Brilinta |
| Boston Scientific Corporation | $2,190.97 | 2020-2025 | Watchman Flx, Comet, General - Therapies |
| Merck Sharp & Dohme LLC | $1,079.86 | 2019-2025 | Verquvo, Belsomra, Januvia |
| Chiesi USA, INC. | $1,012.69 | 2019-2025 | Kengreal, Cleviprex |
| E.R. Squibb & Sons, L.L.C. | $976.00 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $965.81 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $771.62 | 2019-2025 | |
| Abbott Laboratories | $733.70 | 2019-2025 | Amplatzer Amulet, Optis, Pressurewire |
| Pfizer INC. | $569.01 | 2019-2025 | |
| Arbor Pharmaceuticals, INC. | $552.29 | 2019-2022 | |
| Novo Nordisk INC | $506.91 | 2019-2024 | Ozempic, Rybelsus |
| Heartflow, INC. | $402.09 | 2025 | |
| Medtronic Vascular, INC. | $293.48 | 2019-2020 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Feeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.